Status:
COMPLETED
Clinical Features of Severe Patients With COVID-19
Lead Sponsor:
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Conditions:
SARS-CoV2
Eligibility:
All Genders
18-90 years
Brief Summary
As coronavirus disease 2019 (COVID-19) spreads across the world, the intensive care unit (ICU) community must prepare for the challenges associated with this pandemic. Providing an efficient care to t...
Detailed Description
The clinical disease (COVID-19) results in critical illness in about 5% of patients. The aim of the study is to identify predictors of the severe pneumonia caused by the SARS-CoV-2 virus, and to descr...
Eligibility Criteria
Inclusion
- all patients with COVID-19 admitted to the ICU with invasive and noninvasive ventilation
Exclusion
- less than 24 hours in ICU by any reason,
- chronic decompensated diseases with extrapulmonary organ dysfunction (tumour progression, liver cirrhosis, congestive heart failure),
- atonic coma.
Key Trial Info
Start Date :
April 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04450017
Start Date
April 6 2020
End Date
June 30 2020
Last Update
May 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal Research Clinical Center of Federal Medical & Biological Agency
Moscow, Russia, 115682